Why the study?
There was limited information on elderly patients presenting with ST elevation myocardial infarction (STEMI).
Do elderly Asian patients with STEMI have different revascularization rates and outcomes compared to younger patients?
Do elderly Asian patients with STEMI have different revascularization rates and outcomes compared to younger patients?
Elderly Asian patients with STEMI experience significantly higher mortality and receive less revascularization and guideline-directed medical therapy compared to younger patients.
Elderly STEMI outcomes warrant individualized assessment; leaves open whether higher revascularisation rates would improve survival in Asian octogenarians.
Introduction: There is limited information on elderly patients presenting with ST elevation myocardial infarction (STEMI). This study aimed to study the outcomes of elderly Asian patients with STEMI compared to younger patients. Materials and Methods: The study utilised data from 2007 to 2012 from the Singapore Myocardial Infarction Registry, a mandatory national population-based registry. Elderly patients were defined as ≥80 years of age, middle-aged to old (MAO) patients were defined as 45–80 years of age and young patients were defined as ≤45 years of age. The primary outcome of the study was 1-year mortality and secondary outcomes included in-hospital complications and mortality. Results: There were 12,409 STEMI patients with 1207 (9.7%) elderly patients, 10,093 (81.3%) MAO patients and 1109 (8.9%) young patients. Elderly patients had more cardiovascular risk factors and lower rates of total percutaneous coronary intervention (26.0% vs 72.4% vs 85.5%, respectively; P <0.0001) compared to MAO and young patients. They had higher 1-year mortality (60.6% vs 18.3% vs 4.1%, respectively; P <0.0001) when compared to MAO and young patients. Conclusion: Elderly patients with STEMI have poorer outcomes than MAO and young patients. This is potentially attributable to a myriad of factors including age, higher burden of comorbidities and a lesser likelihood of receiving revascularisation and guideline-recommended medical therapy.
No takes yet. Share an insight, caveat, or question.
Cai et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: